🔎 Trials Near Me

Gara Jalqabaatti › Saree Oljoo › Virginia › Norfolk

Qorannoo klinikaalii Saree Oljoo Norfolk, VA keessatti

Qorannoo 16 Saree Oljoo f Norfolk fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

The Vanguard Study: Testing a New Way to Screen for Cancer

Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
  • Sentara Norfolk General Hospital, Norfolk
Umuriin 45 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06995898

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06982521

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates, Norfolk
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
  • Sentara Norfolk General Hospital, Norfolk
Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07102381

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Namoota walitti qabaa jiraSadarkaa 1/2
  • Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07701941

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07060807

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06966700

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • Clinical Trial Site, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07085767

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Namoota walitti qabaa jiraSadarkaa 2
  • Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06797635

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Namoota walitti qabaa jiraSadarkaa 1/2
  • Virginia Cancer Institute, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT05386108

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates, Norfolk
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT05232916

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Namoota walitti qabaa jiraSadarkaa 1/2
  • USOR Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Bit-2026 · NCT05748834

Qorannoo Saree Oljoo magaalota biroo keessatti

Qorannoo biroo Norfolk keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.